{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T15:54:48Z","timestamp":1746114888331,"version":"3.33.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ijcard.2024.132578","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T20:16:47Z","timestamp":1726777007000},"page":"132578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The CNIC polypill (Acetylsalicylic acid\u00a0+\u00a0Atorvastatin\u00a0+\u00a0Rampril) in secondary prevention of cardiovascular disease in patients with type 2 diabetes: A comparative analysis with alternative therapeutic approaches"],"prefix":"10.1016","volume":"418","author":[{"given":"Jos\u00e9 R.","family":"Gonz\u00e1lez-Juanatey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds","family":"Masana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Dalmau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2024.132578_bb0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijcard.2017.07.081","article-title":"Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes","volume":"248","author":"Engelen","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"11","key":"10.1016\/j.ijcard.2024.132578_bb0010","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc08-1013","article-title":"Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors","volume":"31","author":"Giorda","year":"2008","journal-title":"Diabetes Care"},{"issue":"18","key":"10.1016\/j.ijcard.2024.132578_bb0015","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1001\/jama.2022.14914","article-title":"Trends in the association between diabetes and cardiovascular events, 1994-2019","volume":"328","author":"Ke","year":"2022","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ijcard.2024.132578_bb0020","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jval.2017.12.019","article-title":"Economic burden of cardiovascular disease in type 2 diabetes: a systematic review","volume":"21","author":"Einarson","year":"2018","journal-title":"Value Health"},{"issue":"2_suppl","key":"10.1016\/j.ijcard.2024.132578_bb0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/2047487319878371","article-title":"Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications","volume":"26","author":"Dal Canto","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcard.2024.132578_bb0030","first-page":"280","article-title":"Differences in all-cause health care utilization and costs in a type 2 diabetes mellitus population with and without a history of cardiovascular disease","volume":"24","author":"Mehta","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"39","key":"10.1016\/j.ijcard.2024.132578_bb0035","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"issue":"Supplement_1","key":"10.1016\/j.ijcard.2024.132578_bb0040","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc23-S010","article-title":"10. Cardiovascular disease and risk management: standards of Care in Diabetes\u20142023","volume":"46","author":"ElSayed","year":"2022","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ijcard.2024.132578_bb0045","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive Management of Cardiovascular Risk Factors for adults with type 2 diabetes: a scientific statement from the American Heart Association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2024.132578_bb0050","series-title":"World Health Organization-Wellcome Trust meeting Report, 1-3 August","article-title":"Secondary prevention of noncommunicable diseases in low-and middle-income countries through community-based and health service interventions","author":"World Health Organization (WHO)","year":"2001"},{"author":"Ferrer Internacional","key":"10.1016\/j.ijcard.2024.132578_bb0055"},{"author":"Ferrer Internacional","key":"10.1016\/j.ijcard.2024.132578_bb0060"},{"issue":"11","key":"10.1016\/j.ijcard.2024.132578_bb0065","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill strategy in secondary cardiovascular prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2024.132578_bb0070","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijcard.2022.05.015","article-title":"The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: the NEPTUNO study","volume":"361","author":"Gonzalez-Juanatey","year":"2022","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.ijcard.2024.132578_bb0075","doi-asserted-by":"crossref","first-page":"134","DOI":"10.36469\/jheor.2022.39768","article-title":"Cost-effectiveness of the CNIC-Polypill strategy compared with separate Monocomponents in secondary prevention of cardiovascular and cerebrovascular disease in Portugal: the MERCURY study","volume":"9","author":"Aguiar","year":"2022","journal-title":"J. Health Econ. Outcome. Res."},{"key":"10.1016\/j.ijcard.2024.132578_bb0080","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2147\/CEOR.S396290","article-title":"Economic burden associated with the treatment with a cardiovascular Polypill in secondary prevention in Spain: cost-effectiveness results of the NEPTUNO study","volume":"15","author":"Cordero","year":"2023","journal-title":"Clinicoecon Outcom. Res."},{"issue":"7","key":"10.1016\/j.ijcard.2024.132578_bb0085","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.rce.2023.05.001","article-title":"Cost-effectiveness of the CNIC-Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain","volume":"223","author":"Gonzalez-Dominguez","year":"2023","journal-title":"Rev. Clin. Esp. (Barc)."},{"key":"10.1016\/j.ijcard.2024.132578_bb0090","series-title":"Executive Summary of the Report of the 24th WHO Expert Committee on the Selection and Use of Essential Medicines, 24\u201328 April 2023","article-title":"The selection and use of essential medicines","author":"World Health Organization (WHO)","year":"2023"},{"key":"10.1016\/j.ijcard.2024.132578_bb0095","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"journal-title":"J. Hypertens.","year":"2023","author":"Mancia","key":"10.1016\/j.ijcard.2024.132578_bb0100"},{"key":"10.1016\/j.ijcard.2024.132578_bb0105","doi-asserted-by":"crossref","first-page":"S734","DOI":"10.1016\/j.jval.2019.09.1764","article-title":"PMU146 validation and representativeness of the spanish big-pac database: integrated computerized medical records for research into epidemiology, medicines and health resource use (real word evidence)","volume":"22","author":"Sicras-Mainar","year":"2019","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.ijcard.2024.132578_bb0110","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/13696998.2020.1719118","article-title":"Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain","volume":"23","author":"Sicras-Mainar","year":"2020","journal-title":"J. Med. Econ."},{"year":"2024","series-title":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos, BOT Plus 2. Base de Datos de Medicamentos","key":"10.1016\/j.ijcard.2024.132578_bb0115"},{"issue":"19","key":"10.1016\/j.ijcard.2024.132578_bb0120","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1001\/jama.2019.3471","article-title":"Resurgence in diabetes-related complications","volume":"321","author":"Gregg","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ijcard.2024.132578_bb0125","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/jama.2021.9883","article-title":"Trends in prevalence of diabetes and control of risk factors in diabetes among US adults, 1999-2018","volume":"326","author":"Wang","year":"2021","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.ijcard.2024.132578_bb0130","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMsa2032271","article-title":"Trends in Diabetes Treatment and Control in U.S. Adults, 1999\u20132018","volume":"384","author":"Fang","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"33","key":"10.1016\/j.ijcard.2024.132578_bb0135","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1093\/eurheartj\/ehab501","article-title":"Worsening of risk factor control in US diabetic patients: a call to action","volume":"42","author":"Volpe","year":"2021","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ijcard.2024.132578_bb0140","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2337\/dc19-2165","article-title":"Screening for glucose perturbations and risk factor Management in Dysglycemic Patients with Coronary Artery Disease-a Persistent Challenge in need of substantial improvement: a report from ESC EORP EUROASPIRE V","volume":"43","author":"Ferrannini","year":"2020","journal-title":"Diabetes Care"},{"issue":"14","key":"10.1016\/j.ijcard.2024.132578_bb0145","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1177\/2047487318789494","article-title":"Combined use of polypill components in patients with type 2 diabetes mellitus","volume":"25","author":"Janssen","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcard.2024.132578_bb0150","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s12325-020-01285-2","article-title":"Proportion of high-risk\/very high-risk patients in Europe with low-density lipoprotein cholesterol at target according to European guidelines: a systematic review","volume":"37","author":"Bruckert","year":"2020","journal-title":"Adv. Ther."},{"issue":"8","key":"10.1016\/j.ijcard.2024.132578_bb0155","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1177\/2047487318825350","article-title":"Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry","volume":"26","author":"Kotseva","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132578_bb0160","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jacl.2013.09.009","article-title":"Therapeutic practice patterns related to statin potency and ezetimibe\/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease","volume":"8","author":"Toth","year":"2014","journal-title":"J. Clin. Lipidol."},{"issue":"5","key":"10.1016\/j.ijcard.2024.132578_bb0165","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jacl.2013.06.002","article-title":"Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting","volume":"7","author":"Simpson","year":"2013","journal-title":"J. Clin. Lipidol."},{"issue":"12","key":"10.1016\/j.ijcard.2024.132578_bb0170","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/CIRCULATIONAHA.113.003589","article-title":"Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction","volume":"129","author":"Arnold","year":"2014","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.ijcard.2024.132578_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11206004","article-title":"Major adverse cardiovascular events in coronary type 2 diabetic patients: identification of associated factors using electronic health records and natural language processing","volume":"11","author":"Gonz\u00e1lez-Juanatey","year":"2022","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132578_bb0180","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12933-021-01311-9","article-title":"Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial","volume":"20","author":"Schwartz","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132578_bb0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.117.09259","article-title":"Risk of cardiovascular events in patients with diabetes mellitus on \u03b2-blockers","volume":"70","author":"Tsujimoto","year":"2017","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.ijcard.2024.132578_bb0190","first-page":"291","article-title":"Effect of \u03b2-blocker therapy in diabetic patients with stable coronary heart disease: a meta-analysis","volume":"16","author":"Malik","year":"2019","journal-title":"J. Geriatr. Cardiol."},{"issue":"2","key":"10.1016\/j.ijcard.2024.132578_bb0195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jdiacomp.2006.02.005","article-title":"Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes","volume":"21","author":"Mody","year":"2007","journal-title":"J. Diabetes Complicat."},{"issue":"24","key":"10.1016\/j.ijcard.2024.132578_bb0200","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1093\/eurheartj\/ehn478","article-title":"Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry","volume":"29","author":"Mehta","year":"2008","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132578_bb0205","first-page":"53","article-title":"Incremental healthcare resource utilization and expenditures associated with cardiovascular diseases in patients with diabetes: a cross-sectional study","volume":"47","author":"Ebrahimoghli","year":"2022","journal-title":"Iran J. Med. Sci."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132578_bb0210","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/dom.15299","article-title":"Societal health and economic burden of cardiovascular diseases in the population with type 2 diabetes in Qatar. A 10-year forecasting model","volume":"26","author":"Abushanab","year":"2024","journal-title":"Diabetes Obes. Metab."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324012002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324012002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T21:07:12Z","timestamp":1737580032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527324012002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":42,"alternative-id":["S0167527324012002"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132578","relation":{},"ISSN":["0167-5273"],"issn-type":[{"type":"print","value":"0167-5273"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The CNIC polypill (Acetylsalicylic acid\u00a0+\u00a0Atorvastatin\u00a0+\u00a0Rampril) in secondary prevention of cardiovascular disease in patients with type 2 diabetes: A comparative analysis with alternative therapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"132578"}}